RESUMEN
Prostate cancer (PCa) is one of the most common malignancies and cause of cancer death in men. Prostate-specific antigen (PSA) is the most used biomarker in the detection of early PCa. Lately, scientists have been using prostate-specific membrane antigen (PSMA), a glycol-protein that is over-expressed in PCa cells in positron emission tomography/ computed tomography (PET/CT) scans to detect PCa. Gallium-68-PSMA radiotracers, such as 68Ga-PSMA-11, 68Ga-PSMA-617 and 68Ga-PSMA I&T, were firstly introduced in 2011 and fluorine-18-PSMA based radiotracers followed with 18F-PSMA-1007,N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]- 4-18F-fluorobenzyl-L-cysteine(18F-DCFBC) and 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)- pentanedioic acid (18F-DCFPyL), also known as PYLARIFY, being the most used and showed superior results compared to conventional imaging techniques. Differences depending on half-life, clearance and normal organ uptake are being detected through research to determine which of the radiotracers, is the most suitable for each patient. Two of them, 68Ga-PSMA-11 and PLYRIFY, have already been approved by the Food and Drug Administration (FDA). The future of hybrid imaging for PCa is very promising if we consider the advantages of PSMA radiotracers compared to non-PSMA radioligands.
Asunto(s)
Tomografía Computarizada por Tomografía de Emisión de Positrones , Neoplasias de la Próstata , Isótopos de Galio , Radioisótopos de Galio , Humanos , Masculino , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Próstata , Neoplasias de la Próstata/diagnóstico por imagen , Neoplasias de la Próstata/patología , RadiofármacosRESUMEN
PURPOSE: Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain. METHODS: The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed. CONCLUSION: These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.
Asunto(s)
Medicina Nuclear , Europa (Continente) , Humanos , Cintigrafía , Radiofármacos/efectos adversosRESUMEN
PURPOSE: The investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy. METHODS: We prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy. RESULTS: SUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, ß2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET. CONCLUSION: This study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates.
Asunto(s)
Fluorodesoxiglucosa F18 , Mieloma Múltiple , Médula Ósea/diagnóstico por imagen , Humanos , Mieloma Múltiple/diagnóstico por imagen , Mieloma Múltiple/terapia , Células Plasmáticas , Tomografía Computarizada por Tomografía de Emisión de Positrones , Pronóstico , Radiofármacos , Estudios RetrospectivosRESUMEN
Current literature records a glaring discrepancy between the rapid developments and progress of medicine and the simultaneous deterioration of the quality and safety of the provided health care services. Bibliographic data as far as perceptions of quality and safety in nuclear medicine departments are concerned, are limited and frequently ambiguous. Most nuclear medicine departments provide the same types of services, but not the same quality of service, while patients' perceptions are not always matched by the perceptions of health care providers. The multidimensional nature of quality and safety, deriving from the different criteria and standards by which different groups of the population attempt to interpret and evaluate them, justifies these discrepancies, over most of quality's and safety's dimensions studied. Nuclear medicine's unique characteristic of using radiopharmaceuticals, exposing to ionizing radiation affects dramatically these perceptions, irrespective of whether quality and safety assurance measures already cover radiation protection, instrumentation maintenance, radiopharmaceutical handling, and the management of all the other aspects of patient care. On the other end of the spectrum, patient-centred practice, communication and proper information play as a well decisive role in ensuring patients' satisfaction.